NMPA approves Theiboantium drug Fycompa for treatment of seizures at age 12 and over

Recently, Eisai, a Japanese pharmaceutical company, announced that China's NationalDrug(http://Regulatory Authority (NMPA) has approved a new generation of anti-epileptic drug Fycompa (perampanel, Verumpanay) for the treatment of partial seizures in patients aged 12 and overFycompa'sNew Drug(http://Application (NDA) was submitted in September 2018 and was awarded a priority review by NMPA in January 2019 due to significant clinical benefitswith existingdrug(http:// QualifyingFycompa
Fycompa is a first-of-the-first (first-in-class) anti-epileptic drug (AEDs) developed in-house by Veaton, a highly selective, non-competitive AMPA-type glutamate receptor antagonistGlutamate is the main neurotransmitter of the adhesion of seizuresFycompa reduces overexcitement of neurons associated with seizures by targeting ampA receptor-glutamate activity after a targeted synapse, a mechanism that differs from the current lyser anti-epileptic drugs (AEDs) currently available 　　To date, Fycompa has been approved by more than 60 countries worldwide as an adjunct therapy for partial seizure seclampsia (POS, with or without a secondary systemic seizure) in patients 12 years of age and older. 　　Fycompa has also been approved by more than 55 countries worldwide as an adjunct therapy for the treatment of primary, total strong stiffness (PGTC) seizures in people aged 12 and over 　　In the United States, Fycompa is also used as a single drug therapy and complementary therapy for partial seizures (with or without a secondary systemic seizure) in people with epilepsy 4 years and older